The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020
…, TV Pereira, C Locher, L Caquelin… - … Journal of Cancer, 2023 - Wiley Online Library
Concerns have been raised that regulatory programs to accelerate approval of cancer drugs
in cancer may increase uncertainty about benefits and harms for survival and quality of life (…
in cancer may increase uncertainty about benefits and harms for survival and quality of life (…
Data-sharing recommendations in biomedical journals and randomised controlled trials: an audit of journals following the ICMJE recommendations
M Siebert, JF Gaba, L Caquelin, H Gouraud, A Dupuy… - BMJ open, 2020 - bmjopen.bmj.com
Objective To explore the implementation of the International Committee of Medical Journal
Editors (ICMJE) data-sharing policy which came into force on 1 July 2018 by ICMJE-member …
Editors (ICMJE) data-sharing policy which came into force on 1 July 2018 by ICMJE-member …
Intent to share Annals of Internal Medicine's trial data was not associated with data re-use
C Pellen, L Caquelin, A Jouvance-Le Bail… - Journal of Clinical …, 2021 - Elsevier
Objective To explore the impact of the Annals of Internal Medicine (AIM) data-sharing policy
for randomized controlled trials (RCTs) in terms of output from data-sharing (ie publications …
for randomized controlled trials (RCTs) in terms of output from data-sharing (ie publications …
[HTML][HTML] Assessing the magnitude of changes from protocol to publication—a survey on Cochrane and non-Cochrane Systematic Reviews
Objective To explore differences between published reviews and their respective protocols
in a sample of 97 non-Cochrane Systematic Reviews (non-CSRs) and 97 Cochrane …
in a sample of 97 non-Cochrane Systematic Reviews (non-CSRs) and 97 Cochrane …
[HTML][HTML] Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
L Caquelin, M Gewily, W Mottais, C Tebaldi, B Laviolle… - BMC cancer, 2022 - Springer
Background Tivozanib (Fotivda) is an anti-angiogenic tyrosine kinase inhibitor that was
denied access to the US market by the Food and Drug Administration (FDA). In contrast, it was …
denied access to the US market by the Food and Drug Administration (FDA). In contrast, it was …
Pharmacology and pharmacovigilance of protein kinase inhibitors
Protein kinase inhibitors experienced their advent in the 2000s. Their market introduction
made it possible to constitute a class of targeted therapies administered orally. This name was …
made it possible to constitute a class of targeted therapies administered orally. This name was …
Meta-research studies should improve and evaluate their own data sharing practices
IA Cristea, F Naudet, L Caquelin - Journal of Clinical Epidemiology, 2022 - Elsevier
Data sharing is gradually becoming a requirement across all fields of science, owing to its
key benefits in verifying the reproducibility of findings and reusing existent data for new …
key benefits in verifying the reproducibility of findings and reusing existent data for new …
Re-use of trial data in the first 10 years of the data-sharing policy of the Annals of Internal Medicine: a survey of published studies
C Pellen, L Caquelin, AJL Bail, J Gaba, M Vérin… - medRxiv, 2020 - medrxiv.org
Background The Annals of Internal Medicine (AIM) has adopted a policy encouraging data-sharing
since 2007. Objective To explore the impact of the AIM data-sharing policy for …
since 2007. Objective To explore the impact of the AIM data-sharing policy for …
[CITATION][C] Meta-analysis of phase I dose-finding studies: Application for protein kinase inhibitors developed in oncology
L Caquelin, P Badra, M Ursino, B Laviolle… - EPICLIN 2023 17e …, 2023 - hal.science
Meta-analysis of phase I dose-finding studies: Application for protein kinase inhibitors
developed in oncology - Archive ouverte HAL Accéder directement au contenu …
developed in oncology - Archive ouverte HAL Accéder directement au contenu …
[CITATION][C] Dose-finding designs for development of small-molecule tyrosine kinase inhibitors in oncology.
C Locher, L Caquelin, N Florian - 2019 - osf.io